- |||||||||| RT-100 / Renova Therap
Journal: Sex differences in corticospinal excitability and quadriceps performance after ACL reconstruction. (Pubmed Central) - Nov 8, 2023
Quadriceps performance (peak torque, PT; rate of torque development from onset to 100ms, RTD100; and RTD from 100-200ms, RTD200) and CSE (active motor threshold, AMT; slope of the stimulus response curve, SR curve slope) were measured using an isokinetic dynamometer (HUMAC NORM) and transcranial magnetic stimulation respectively...Females after ACLR had worse surgical limb quadriceps PT than control males and slower RTD100 and RTD200 than control males and control females. Higher CSE in males after ACLR may point to a potentially adaptive neurological change in males post-ACLR and indicate greater need for novel interventions to address cortical drive in females after ACLR.
- |||||||||| RT-100 / Renova Therapeutics
Journal: Rate of torque development as a discriminator of playing level in collegiate female soccer players. (Pubmed Central) - Sep 10, 2022
Our findings indicate that RTD may be a better parameter than peak torque at differentiating between playing level in collegiate female soccer players. The discriminant analysis thresholds for the RTD variables demonstrated good sensitivity and specificity, and therefore, may be used as indices to identify players with a high degree of soccer playing ability.
- |||||||||| RT-100 / Renova Therapeutics
Journal: HyperArc Dosimetric Validation for Multiple Targets Using Ionization Chamber and RT-100 Polymer Gel. (Pubmed Central) - Aug 26, 2022
For each target volume, the obtained results in terms of gamma index passing rate show an agreement >95% with 5% 2 mm and 3% 2 mm criteria for both 2D and 3D distributions. The obtained results confirmed that the use of a single isocenter for multiple lesions reduces the treatment time without compromising accuracy, even in the case of target volumes that are quite distant from the isocenter.
- |||||||||| RT-100 / Renova Therapeutics
Energy And Carbohydrate Intake Are Associated With Quadriceps Rate Of Torque Development Following ACL Injury (Exhibit Hall F) - Jun 2, 2022 - Abstract #ACSM2022ACSM_1149;
Our results show total energy and carbohydrate intake positively associate with strength indices following ACL injury. These findings underscore the importance of nutritional status to support functional recovery following ACL injury and highlight the need to study the role of carbohydrate intake needs during recovery from ACL injury.
- |||||||||| RT-100 / Renova Therapeutics
Knee Extensor Rate Of Torque Development Assessment Post-acl Reconstruction: Does Sampling Rate Matter? (Exhibit Hall F) - Jun 2, 2022 - Abstract #ACSM2022ACSM_1054;
RTD was characterized with multiple variables: from contraction onset to 50, 100, and 200 ms (RTD0-50, RTD0-100, and RTD0-200, respectively), in sequence from 50 to 100 ms and 100 to 200 ms (RTD50-100 and RTD100-200), as the slope of 20-80% of peak torque (RTD20-80), and as the maximal instantaneous slope (RTDPeak)... Involved limb RTD and RTD LSI for RTD0-200, RTD20-80, and RTDPeak can be accurately assessed with reduced sampling rates, thereby facilitating use of clinically available equipment for assessing knee extensor RTD post-ACLR.
- |||||||||| RT-100 / Renova Therapeutics
Clinical, Journal: Changes in Knee Extension and Flexion Maximal and Rapid Torque Characteristics During a Collegiate Women's Soccer Season. (Pubmed Central) - May 6, 2022
Peak torque (PT) and rate of torque development (RTD) at 50 (RTD50), 200 (RTD200), and 100-200 (RTD100-200) milliseconds were extracted from each MVIC for both legs...These findings suggest that participation in a soccer season can change maximal and rapid torque production of the knee extensors and flexors. Coaches and clinicians should consider incorporating a season-long strength training and maintenance plan for soccer players with the aim to improve athletic performance and minimize the risk of musculoskeletal injuries to the lower extremities.
- |||||||||| RT-100 / Renova Therapeutics
Journal: An Analysis of Retinal Nerve Fiber Layer Thickness before and after Pituitary Adenoma Surgery and its Correlation with Visual Acuity. (Pubmed Central) - Mar 17, 2021
Preoperative visual acuity, fundus and RNFL thickness were calculated using spectral-domain OCT Optovue, Heidelberg Engineering, Heidelberg, Germany (RT 100 version 5.1), and postoperative measurement was done after 1 and 3 months...It was also found that once optic disc pallor sets due to chronic compression, then chances of its reversion to normal depend on its grading: only mild pallor disc has some chance to revert to normal, whereas moderate and severe pallor do not revert to normal. RNFLT and optic disc can be used as prognostic factors for evaluation of visual outcome in pituitary adenoma surgery.
- |||||||||| RT-100 / Renova Therapeutics
Journal: EFFECTS OF ISOKINETIC ECCENTRIC VERSUS TRADITIONAL LOWER BODY RESISTANCE TRAINING ON MUSCLE FUNCTION: EXAMINING A MULTIPLE-JOINT SHORT TERM TRAINING MODEL. (Pubmed Central) - Dec 29, 2019
The eccentric group also yielded moderate improvements in the middle-late phase RTD (RTD100-200; ES = 0.51 and 0.54 for the knee flexors and extensors, respectively), whereas the TLP group showed small-moderate improvements (ES = 0.37)...Eccentric multi-joint training induced significant improvements for lower body strength in a short amount of time in a trained population. These accelerated adaptations and also the lowered energy requirements of eccentric exercise may be useful for clinicians or practitioners when prescribing training programs for those who are injured, sedentary, or elderly, who are in need of time efficient muscle function improvements.
- |||||||||| RT-100 / Renova Therapeutics
Trial completion date, Trial initiation date, Trial primary completion date: FLOURISH: AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure (clinicaltrials.gov) - Dec 20, 2018
P3, N=536, Not yet recruiting,
The FLOURISH study, which received fast track designation from the Food and Drug Administration in December 2017, will further investigate the role of a one-time intracoronary injection of RT-100 in reducing HF hospitalizations and will serve as a registration trial (potentially pivotal investigation) for RT-100 as a treatment for HFrEF. Trial completion date: Sep 2022 --> Jun 2023 | Initiation date: Sep 2018 --> Jun 2019 | Trial primary completion date: Sep 2019 --> Jun 2020
- |||||||||| RT-100 / Renova Therapeutics
Trial completion, Trial completion date: AC6 Gene Transfer for CHF (clinicaltrials.gov) - Feb 9, 2018
P1/2, N=56, Completed,
Trial completion date: Feb 2022 --> Sep 2022 | Initiation date: Feb 2018 --> Sep 2018 | Trial primary completion date: Feb 2019 --> Sep 2019 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Nov 2017
- |||||||||| RT-100 / Renova Therapeutics
Enrollment closed, Trial primary completion date: AC6 Gene Transfer for CHF (clinicaltrials.gov) - Jan 8, 2015
P1/2, N=56, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Nov 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015
- |||||||||| RT-100 / Renova Therapeutics
Enrollment change: AC6 Gene Transfer for CHF (clinicaltrials.gov) - Jul 16, 2013
P1/2, N=56, Recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Jan 2015 N=72 --> 56
|
